NCCN guideline in 2021.v2 also suggested continual EGFR‐TKI with or without local therapy in EGFRm advanced/metastatic NSCLC patients with asymptomatic PD and symptomatic limited PD after first‐line erlotinib, afatinib, gefitinib, or osimertinib therapy, except for the occurrence of T790M. Here, EGFR is linked to non-small cell lung carcinoma.